FOXO4-DRI
Research OnlyAlso known as: FOXO4-D-Retro-Inverso, FOXO4-DRI Peptide, Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Research Statistics
In vitro senolytic only; single research group, no human studies, no independent replication.
Research Dossier
Overview
What is FOXO4-DRI and what does the research say?
Mechanism of Action
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells by disrupting the FOXO4-p53 interaction that allows these “zombie cells” to evade apoptosis.
How It Works (Simplified)
FOXO4-DRI triggers selective death of senescent cells through a targeted mechanism:
Competes with endogenous FOXO4 for p53 binding, breaking the survival mechanism that keeps senescent cells alive.
Freed from nuclear sequestration, p53 translocates to mitochondria and initiates the intrinsic apoptosis pathway.
Only senescent cells depend on FOXO4-p53 for survival - normal cells are unaffected by the disruption.
D-amino acids in reversed sequence resist protease degradation while maintaining the same binding surface.
Scientific Pathways
Senescent Cell Survival Mechanism (What FOXO4-DRI Disrupts)
DNA damage/stress → p53 activation
↓
FOXO4 binds p53 → Nuclear sequestration
↓
p53 prevented from mitochondrial translocation
↓
Apoptosis blocked → Senescent cell survivesFOXO4-DRI Mechanism (Senolytic Action)
FOXO4-DRI enters cell → Competes for p53 binding
↓
Native FOXO4-p53 complex disrupted
↓
p53 released → Mitochondrial translocation
↓
Intrinsic apoptosis → Senescent cell deathKey Research: Baar MP et al. (2017) demonstrated selective senolysis in aged mice with restoration of fitness, fur density, and renal function. PMID:28340339
Important Limitations
- No human trials — All efficacy data is from mouse studies
- No independent replication — Findings primarily from originating laboratory
- Safety profile unknown — Long-term effects of senescent cell depletion unclear
- Complex synthesis — D-retro-inverso peptides are difficult to manufacture
- Product quality concerns — Research-grade only, variable purity
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
FOXO4-DRI enters cells via cell-penetrating properties. Competes with endogenous FOXO4 for p53 binding. Apoptosis of senescent cells begins within hours in vitro.
In mouse studies, treatment three times per week for 3-4 weeks produced measurable effects. Senescent cell burden reduced (p16, p21 markers). SASP factors decreased.
After several weeks of treatment, aged mice showed restored running wheel activity, improved fur density, and enhanced renal function. Tissue homeostasis improvements observed.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate FOXO4-DRI product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining FOXO4-DRI with other peptides. Based on published research and mechanistic considerations.
Epithalon
CompatibleDifferent longevity mechanisms - FOXO4-DRI clears senescent cells while epithalon targets telomerase. No interaction studies but theoretically complementary.
Mots-C
CompatibleDifferent mechanisms - FOXO4-DRI clears senescent cells while MOTS-c targets AMPK metabolic pathways. No known interactions.
Ss-31
CompatibleDifferent targets - SS-31 protects mitochondria while FOXO4-DRI clears senescent cells. Potentially complementary for aging intervention.
Humanin
CautionOpposing mechanisms - humanin is anti-apoptotic while FOXO4-DRI promotes apoptosis in senescent cells. Could potentially counteract senolytic effects.
BPC-157
CautionUncertain interaction - BPC-157 promotes tissue repair which may involve senescent cell signaling. Effects on senolytic activity unknown.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare FOXO4-DRI
FOXO4-DRI Calculators
Related Peptides
Endoluten
Pineal cytamin, Pineal gland peptides, A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Epithalon
Epitalon, Epithalone, AGAG +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan. 2025 independent Western research confirmed telomerase activation in vitro. Still not approved anywhere; no controlled human clinical trials.
Glutathione
GSH, L-Glutathione, Reduced Glutathione +1 more
The master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
Humanin
HN, HNG, S14G-Humanin +2 more
A 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies. Represents a novel class of signaling molecules encoded within mitochondrial DNA. Extensive academic research with emerging interest in aging, metabolic disease, and neurodegeneration, but no approved clinical applications.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide, MOTS-C peptide
A 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.
SHLP-2
Small Humanin-Like Peptide 2, SHLP2, Mitochondrial-Derived Peptide 2
A 26-amino acid mitochondria-derived peptide (MDP) discovered in 2016 from the same mitochondrial DNA region as humanin. Shows cytoprotective, metabolic, and potential longevity effects in preclinical studies. Part of an emerging class of mitochondrial signaling molecules, but human therapeutic data is lacking.